Survival outcome of different treatment sequences in patients with locally advanced and metastatic pancreatic cancer
Abstract Background Despite some therapeutic advances, improvement in survival rates of unresectable and/or metastatic pancreatic ductal adenocarcinoma (PDAC) has been minimal over recent decade. We aimed to evaluate the impact of different treatment sequences on clinical outcomes of advanced PDAC a...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-01-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-024-11823-8 |
| _version_ | 1797355690052812800 |
|---|---|
| author | Mengjiao Fan Guochao Deng Yue Ma Haiyan Si Zhikuan Wang Guanghai Dai |
| author_facet | Mengjiao Fan Guochao Deng Yue Ma Haiyan Si Zhikuan Wang Guanghai Dai |
| author_sort | Mengjiao Fan |
| collection | DOAJ |
| description | Abstract Background Despite some therapeutic advances, improvement in survival rates of unresectable and/or metastatic pancreatic ductal adenocarcinoma (PDAC) has been minimal over recent decade. We aimed to evaluate the impact of different treatment sequences on clinical outcomes of advanced PDAC at our academic institution. Methods In this single institution retrospective analysis, we assessed characteristics and survival rates of unresectable and/or metastatic pancreatic PDAC patients who started a systemic treatment between 01/2015 and 12/2021. Survival analyses were performed by Kaplan-Meier and Cox proportional hazards model. Results The number of 285 patients received at least two lines of treatment, but only 137 patients were suitable for third-line treatment. Subgroup analysis showed that thirty-seven patients received A line (gemcitabine/nab-paclitaxel or nab-paclitaxel combined therapy to FOLFIRINOX) therapy, 37 patients received B line (nab-paclitaxel combined therapy to gemcitabine combined therapy to FOLFIRINOX) therapy, 21 patients received C line (nab-paclitaxel combined therapy to gemcitabine combined therapy to oxaliplatin or irinotecan combined therapy) therapy. Survival rates for different treatment lines were significantly different and median overall survival (OS) was 14.00, 18.00, and 14.00 months, respectively (p<0.05). Conclusion Our study provides real-world evidence for the effectiveness of different treatment sequences and underscores the treatment sequences on survival outcome when considering the entire management in advanced PDAC. |
| first_indexed | 2024-03-08T14:14:44Z |
| format | Article |
| id | doaj.art-002bac9f900c484b892871fc315ce95d |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-03-08T14:14:44Z |
| publishDate | 2024-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-002bac9f900c484b892871fc315ce95d2024-01-14T12:26:27ZengBMCBMC Cancer1471-24072024-01-0124111110.1186/s12885-024-11823-8Survival outcome of different treatment sequences in patients with locally advanced and metastatic pancreatic cancerMengjiao Fan0Guochao Deng1Yue Ma2Haiyan Si3Zhikuan Wang4Guanghai Dai5Medical School of Chinese People’s Liberation ArmyDepartment of oncology, The Fifth Medical Center, Chinese People’s Liberation Army General HospitalMedical School of Chinese People’s Liberation ArmyDepartment of oncology, The Fifth Medical Center, Chinese People’s Liberation Army General HospitalDepartment of oncology, The Fifth Medical Center, Chinese People’s Liberation Army General HospitalDepartment of oncology, The Fifth Medical Center, Chinese People’s Liberation Army General HospitalAbstract Background Despite some therapeutic advances, improvement in survival rates of unresectable and/or metastatic pancreatic ductal adenocarcinoma (PDAC) has been minimal over recent decade. We aimed to evaluate the impact of different treatment sequences on clinical outcomes of advanced PDAC at our academic institution. Methods In this single institution retrospective analysis, we assessed characteristics and survival rates of unresectable and/or metastatic pancreatic PDAC patients who started a systemic treatment between 01/2015 and 12/2021. Survival analyses were performed by Kaplan-Meier and Cox proportional hazards model. Results The number of 285 patients received at least two lines of treatment, but only 137 patients were suitable for third-line treatment. Subgroup analysis showed that thirty-seven patients received A line (gemcitabine/nab-paclitaxel or nab-paclitaxel combined therapy to FOLFIRINOX) therapy, 37 patients received B line (nab-paclitaxel combined therapy to gemcitabine combined therapy to FOLFIRINOX) therapy, 21 patients received C line (nab-paclitaxel combined therapy to gemcitabine combined therapy to oxaliplatin or irinotecan combined therapy) therapy. Survival rates for different treatment lines were significantly different and median overall survival (OS) was 14.00, 18.00, and 14.00 months, respectively (p<0.05). Conclusion Our study provides real-world evidence for the effectiveness of different treatment sequences and underscores the treatment sequences on survival outcome when considering the entire management in advanced PDAC.https://doi.org/10.1186/s12885-024-11823-8Pancreatic ductal adenocarcinomaTreatment landscapeTreatment patternsTreatment sequencesNew chemotherapy regimensIrinotecan |
| spellingShingle | Mengjiao Fan Guochao Deng Yue Ma Haiyan Si Zhikuan Wang Guanghai Dai Survival outcome of different treatment sequences in patients with locally advanced and metastatic pancreatic cancer BMC Cancer Pancreatic ductal adenocarcinoma Treatment landscape Treatment patterns Treatment sequences New chemotherapy regimens Irinotecan |
| title | Survival outcome of different treatment sequences in patients with locally advanced and metastatic pancreatic cancer |
| title_full | Survival outcome of different treatment sequences in patients with locally advanced and metastatic pancreatic cancer |
| title_fullStr | Survival outcome of different treatment sequences in patients with locally advanced and metastatic pancreatic cancer |
| title_full_unstemmed | Survival outcome of different treatment sequences in patients with locally advanced and metastatic pancreatic cancer |
| title_short | Survival outcome of different treatment sequences in patients with locally advanced and metastatic pancreatic cancer |
| title_sort | survival outcome of different treatment sequences in patients with locally advanced and metastatic pancreatic cancer |
| topic | Pancreatic ductal adenocarcinoma Treatment landscape Treatment patterns Treatment sequences New chemotherapy regimens Irinotecan |
| url | https://doi.org/10.1186/s12885-024-11823-8 |
| work_keys_str_mv | AT mengjiaofan survivaloutcomeofdifferenttreatmentsequencesinpatientswithlocallyadvancedandmetastaticpancreaticcancer AT guochaodeng survivaloutcomeofdifferenttreatmentsequencesinpatientswithlocallyadvancedandmetastaticpancreaticcancer AT yuema survivaloutcomeofdifferenttreatmentsequencesinpatientswithlocallyadvancedandmetastaticpancreaticcancer AT haiyansi survivaloutcomeofdifferenttreatmentsequencesinpatientswithlocallyadvancedandmetastaticpancreaticcancer AT zhikuanwang survivaloutcomeofdifferenttreatmentsequencesinpatientswithlocallyadvancedandmetastaticpancreaticcancer AT guanghaidai survivaloutcomeofdifferenttreatmentsequencesinpatientswithlocallyadvancedandmetastaticpancreaticcancer |